Clinical monitoring plan for medical devices in Russia — mandatory for Class 3 and implantable Class 2b from March 2025
Medical device manufacturers are accustomed to thinking that their work with the regulator ends the moment they receive a registration certificate. This misconception is becoming increasingly costly. Roszdravnadzor now has the authority to suspend registration certificates in the event of post-market surveillance violations, and EAEU regulations explicitly obligate manufacturers to systematically collect safety and performance data throughout the entire period a device is on the market.
Post-Market Clinical Monitoring (PMCM): a risk management tool whose outcomes can determine the fate of a registration certificate.
What Changed and Why
Historically, post-market surveillance of medical devices relied on a reactive model: complaints were collected, and the regulator responded to incidents. The mechanism was inefficient. Major international recalls — including metal-on-metal hip implants and ruptured silicone breast implants — demonstrated that a post-factum response comes too late. The European Union shifted to a proactive model with the adoption of Regulation (EU) MDR 2017/745: clinical evaluation became a continuous process, and Post-Market Clinical Follow-up (PMCF) became a mandatory component of a device’s lifecycle.
In the EAEU, a similar shift occurred via Decision of the Council of the Eurasian Economic Commission No. 46 dated February 12, 2016, «On the Rules for Registration and Examination of Safety, Quality, and Performance of Medical Devices» (as amended on March 30, 2023) (hereinafter — Decision No. 46). This document established the requirement to include, as part of the registration dossier, a plan for collecting and analyzing data on device safety and performance at the post-market stage — mandatory for all risk classes.
In Russia, the mandatory nature and practical content of the clinical monitoring plan are codified in Government Decree No. 1684 dated November 30, 2024, «On Approval of the Rules for State Registration of Medical Devices» (as amended on October 27, 2025) (hereinafter — Decree No. 1684), which entered into force on March 1, 2025, replacing Decree No. 1416 of 2012. Not only has the substance of these requirements changed — the consequences of non-compliance have too.
What the Regulatory Acts Require
Decision No. 46 mandates a data collection plan as a compulsory element of the registration dossier for all potential risk classes. Suspension of a registration certificate can occur, among other grounds, «based on the results of monitoring the safety, quality, and performance of medical devices in the post-registration period — upon detection of a potential serious threat to human health» (para. 114 of the Rules to Decision No. 46).
Decree No. 1684 concretizes these requirements with regard to Russian specificities. For Class 3 medical devices and Class 2b implantable devices, a mandatory clinical monitoring plan has been introduced — it is explicitly listed among the documents to be submitted at registration (paras. 65 and 87 of Decree No. 1684 in the original edition; in the edition of October 27, 2025, the relevant provisions were relocated to the section on registration specifics). Failure to submit a clinical monitoring report within the prescribed timeframe entitles the regulator to first suspend state registration for 30 working days, and subsequently issue a decision to cancel state registration (subpara. (i) of para. 137 of Decree No. 1684).
The gap between the pre-registration and post-registration periods has effectively been closed: monitoring data can now serve as the basis for either amending the registration dossier or forcibly withdrawing the device from the market.
| Parameter | Prior to Decree No. 1684 (Decree No. 1416) | After Decree No. 1684 (from March 1, 2025) |
|---|---|---|
| Mandatory nature of the monitoring plan | For specific classes, at the discretion of the expert institution | Mandatory for Class 2b (implants) and Class 3; recommended for others |
| Deadline for report submission | Not clearly defined | Established by the procedure for reporting adverse events by medical device market participants |
| Consequences of non-submission | Administrative measures | Suspension of registration for 30 working days + threat of cancellation |
| Report format | Arbitrary | Regulated by the Roszdravnadzor procedure |
What the Plan Includes and How to Draft It
A clinical monitoring plan is not a one-off document submitted during registration and then set aside. It is the protocol of a living system that collects and analyzes data throughout the device’s entire lifecycle.
The structure of the plan centers on three questions: what clinical gaps exist in the current evidence base, what methods will be used to close those gaps, and what criteria will be used to evaluate the results.
Identification of gaps. The starting point is the clinical evidence report on device safety and performance, compiled for the registration dossier. Typical gaps include: insufficient data on the long-term stability of implants, limited information on use in pediatric or elderly patients, and a lack of data on rare adverse events that cannot be detected in small pre-registration sample sizes.
Data collection methods. Methods are divided into general and specific. General methods encompass systematic literature reviews, post-market database analyses, and user feedback collection. Specific methods include prospective or retrospective clinical studies, patient registries, and medical record surveys. The choice of method is determined by the device’s risk class and the volume of data already accumulated; for Class 3 and Class 2b implantable devices, specific methods are effectively mandatory.
Acceptance criteria. This is the most vulnerable area in most plans. Regulators reject vague language such as «the device is safe.» Measurable threshold values are required — for example: «the rate of infectious complications at the implantation site shall not exceed 2% based on the current state of medical practice» or «the rate of restenosis at 12 months shall be no more than 15%.»
A separate section must outline the action plan in the event adverse results are detected. The regulator needs to see that the manufacturer has thought through this scenario in advance. This section is frequently absent, and its absence is read by reviewers as a sign of an immature quality management system.
Connection to the Quality Management System
PMCM does not operate in isolation from the Quality Management System (QMS). Monitoring data must feed into the risk management process automatically, not only upon request. If monitoring reveals a new adverse effect or an increase in the frequency of a known complication, the manufacturer is obligated to initiate Corrective and Preventive Actions (CAPA). This may entail design modifications, updates to the Instructions for Use (IFU), or a voluntary batch recall.
Monitoring data serves as an input for updating the risk analysis report. Pursuant to Decision of the Council of the Eurasian Economic Commission No. 106 dated November 10, 2017, on QMS requirements for medical devices, manufacturers must keep their system current with post-market data. The cycle runs as follows: monitoring data feeds into risk assessment, the dossier is updated based on the outcomes, and the adjusted monitoring plan covers the next period.
Software as a Medical Device (SaMD) and artificial intelligence-based solutions require a dedicated approach. Decree No. 1684 introduced special conditions for such products: where a device features built-in automated data transmission to the Roszdravnadzor information system, the manufacturer benefits from a simplified procedure for introducing amendments when updating software versions. This creates a direct link between monitoring algorithm performance and the regulatory status of the device.
Practical Mistakes That Trigger Expert Objections
Regulatory practice in the medical device sector reveals several persistent errors that recur from dossier to dossier.
Disconnection between the plan and the report. A manufacturer describes certain methods in the plan but presents entirely different data in the report without explaining the discrepancy. Reviewers classify this as a violation of the monitoring system’s integrity.
Lack of statistical justification for sample size. Using small sample sizes without calculating statistical power is not accepted as evidence. If the objective is to confirm that the complication rate does not exceed 5%, with a desired precision of 1% and a 95% confidence level, the minimum calculated sample is approximately 1,825 patients. An arbitrary figure such as «50 responses» is not considered scientifically justified.
Ignoring negative data. Attempting to conceal or downplay unfavorable results destroys regulatory trust. A transparent account of adverse events paired with an analysis of the corrective measures taken is a mark of a mature QMS, not a reason for sanctions.
Lack of connection to CAPA. If monitoring identifies a problem but the report contains no reference to initiated corrective actions, this constitutes a gap in the quality management process. The regulator is entitled to classify such a gap as a systemic failure.
What to Do
Audit active registration dossiers. Verify that every dossier contains a data collection plan for safety and performance. For Class 2b (implantable) and Class 3 devices, confirm the presence of a clinical monitoring plan as a standalone document. The absence of a plan is grounds for amending the dossier in accordance with Section VI of Decree No. 1684 (amendments requiring expert review).
Update clinical monitoring plans. For every Class 2b (implants) and Class 3 device, draft or update the plan with concrete objectives, methods, sample size calculations, and measurable acceptance criteria. This is best done before Roszdravnadzor issues an official inquiry: a reactive approach is far more costly than a preventive one.
Synchronize PMCM with the QMS. Establish a procedure for transferring data from the monitoring system into the risk management process. The Standard Operating Procedure (SOP) for CAPA must describe the scenario in which «monitoring detects an adverse event.» This requirement is verified during manufacturing site inspections.
Establish reporting timelines. The procedure for submitting clinical monitoring reports is governed by the Ministry of Health’s regulatory act on reporting adverse events by medical device market participants. Add scheduled report preparation dates to your corporate regulatory calendar.
Verify the status of the authorized representative. For foreign manufacturers, the expiration of an authorized representative’s powers without updating the dossier information serves as an independent ground for suspension and subsequent cancellation of registration (subpara. (e) of para. 137 of Decree No. 1684, entering into force on September 1, 2026).
Post-market monitoring is more demanding than pre-market clinical studies in one fundamental respect: it never ends. Regulators understand this and are holding manufacturers to this standard with increasing consistency. A system built before the first inquiry from Roszdravnadzor functions as an asset. A system built in response to one functions as a liability.
Regulatory Framework:
1. Federal Law dated November 21, 2011, No. 323-FZ «On the Basics of Health Protection of Citizens in the Russian Federation» (as amended on July 31, 2025).
2. Decision of the Council of the Eurasian Economic Commission dated February 12, 2016, No. 46 «On the Rules for Registration and Examination of Safety, Quality, and Performance of Medical Devices» (as amended on March 30, 2023).
3. Government Decree of the Russian Federation dated November 30, 2024, No. 1684 «On Approval of the Rules for State Registration of Medical Devices» (as amended on October 27, 2025).
4. Decision of the Council of the Eurasian Economic Commission dated November 10, 2017, No. 106 «On Requirements for the Implementation, Maintenance, and Evaluation of the Quality Management System of Medical Devices.»
5. Decision of the Council of the Eurasian Economic Commission dated February 12, 2016, No. 27 «On General Safety and Performance Requirements for Medical Devices.»